REPLIGEN CORP
Company Stats
- Market Cap
- $10.8B
- as of Sep 30, 2026
- Shares Outstanding
- 63.9M
- Free Float
- 87.7%
Income Statement
- Revenue
- $738.3M
- Operating Income
- $55.2M
- Net Income
- $48.9M
- EBITDA
- $94.9M
- Revenue Growth, 3Y
- -2.7%
- FCF Margin, 3Y Avg
- 16.2%
- FCF Margin, Worst Year
- 12.3%
Cash Flow
- Free Cash Flow
- $93.9M
- FCF Yield
- 0.9%
- Owner FCF Yield
- 0.6%
Balance Sheet
- Cash & Equivalents
- $566.0M
Returns & Capital
- Buyback Yield, 3Y Avg
- 0.0%
- SBC, 3Y Avg
- $35.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $738.3M | $93.9M | 12.7% |
| FY2024 | $634.4M | $149.7M | 23.6% |
| FY2023 | $632.4M | $77.7M | 12.3% |
| FY2022 | $801.5M | $87.2M | 10.9% |
| FY2021 | $670.5M | $51.9M | 7.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 8, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 6, 2026
Deals
Repligen Completes $1.5 Billion BioLife Solutions Acquisition
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 22, 2026
Deals
Repligen to Buy BioLife Solutions in $1.5 Billion Mixed Deal
Repligen Completes $1.5 Billion BioLife Solutions Acquisition
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 22, 2026
Deals
Repligen to Buy BioLife Solutions in $1.5 Billion Mixed Deal